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under pin it. The developed Guideline presents the main concepts of AD technique, 
examples of materials and forms necessary for documentation and evaluation of 
visits performance, and detailed information of each stage necessary to conduct 
an AD Program.
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State and ProSPectS of PHarmacoeconomicS training in Ukraine
Zalis’ka O, Maksymovych N, Leleka M, Piniazhko O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Objectives: Reforming experience of health care in Western countries (Canada, 
USA, UK and other European countries) demonstrates the need for standardiza-
tion of medical and pharmaceutical care for population, taking into account the 
results of pharmacoeconomic analysis, it can reduce health care costs by 10-20 %.In 
Ukraine Prof. Olha Zalis’ka conducted theoretical bases and pharmacoeconomic 
analysis and creation of educational and methodical system of pharmacoeconom-
ics for pharmacists during 1999-2003. MethOds: From 2003 the study of discipline 
“Pharmacoeconomics” was included in curriculum of pharmacists on specialty 
“Pharmacy” and “Clinical Pharmacy” and for postgraduate training of pharmacists 
in the specialty “Economy and management of pharmacy “ and “General pharmacy 
“in Ukraine. Results: Zalis’ka Olha defended doctoral thesis “The theoretical basis 
and practical use of Pharmacoeconomics in Ukraine “ in 2004. It was published 
5 manuals “Pharmacoeconomics” (2000), “The Bases of Pharmacoenomics (2002), 
2007, 2014, which approved by Ministry of Health and Ministry of Education and 
Science of Ukraine for using of 20 pharmaceutical faculties of medical universities.
In 2008 we created ISPOR Ukraine Chapter at the Danylo Halytsky Lviv National 
Medical University (www.ispor.org / local_chapter / Ukraine) . USPOR develops and 
implements the theoretical, practical and educational areas of pharmacoeconom-
ics in Ukraine. To spread knowledge and increase access of local experts set up 
special website in ukrainian (www.uspor.org.ua), which presents the main domes-
tic results. In the postgraduate training of pharmacists we use distance learning 
program (IDL), which are available in Ukrainian. cOnclusiOns: We implemented 
the pharmacoeconomics in requirements of the “Concept of Pharmaceutical Sector 
of Health during 2011-2020”, which claim the use of pharmacoeconomics methods 
in governmental programs, providing formulary system for in-patients.We work in 
MoH Commission of Ukraine which integrates the results of pharmacoeconomic 
studies into practice to determine the list of medicines for state programs for social 
health insurance.
HealtH care USe & Policy StUdieS – Health technology assessment  
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BencHmarking HealtH tecHnology aSSeSSment (Hta) agencieS 
for Setting StandardS on PHarmacoeconomic, Pricing, evidence, 
and general SUBmiSSion reqUirementS: develoPment of a 
mUltidimenSional rating Scale
Mazumder D1, Kapoor A1, Gwatkin N2, Medeiros C3
1Optum Global Solutions, Noida, India, 2Geni Biopharma, Hampshire, UK, 3Optum Life Sciences, 
Minneapolis, MN, USA
Objectives: To reliably and quantitatively benchmark Health Technology 
Assessment (HTA) agencies using a single global benchmarking sys-
tem. MethOds: Literature search was conducted to identify surveys or reports 
evaluating different HTA agencies on a common scale. Using published literature, 
attributes deemed crucial for benchmarking HTA agencies were identified. In col-
laboration with clinical and actuarial experts, we developed a Likert scale to serve 
the basis for comparing key attributes of HTA submission process, i.e. pharma-
coeconomic, pricing, evidence, and general submission requirements. Results: 
Few publications have benchmarked HTA agencies against good practice and 
processes, with no published scale quantitatively assessing HTA agencies for 
attributes of submission requirements. Using identified literature and expert 
opinion, a unique Likert scale was developed with 77 questions. Each question 
were marked on a scale of 0-5, with higher score (4 or 5) indicating best practice 
or ease of accession and low score (0 or 1) indicating lack of guidance or difficulty 
in accession. As a limitation, each category may not have all options from 0-5. 
These 77 questions form 18 best practice principles, and in turn six functional 
domains, i.e. transparency, process, technical, equity, speed and implementation. 
Each domain has a unique significance: transparency - clear unbiased process, 
independent from health system; process - values innovation and prioritizes high 
value impact medicines; technical - defines and manages uncertainty to under-
stand the totality of benefit; equity - takes into account full societal benefit and 
not just health costs; speed - delivers decisions in timely manner to meet innova-
tion and timeliness; implementation - performs clear audit to ensure guidance 
is followed. cOnclusiOns: Our scale provides a new approach to benchmark 
and differentiate HTA agencies in terms of adherence to best practice and ease 
of accession. Further research is required to consider individual market needs 
driving the HTA submission standards.
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análiSiS de viSioneS y PercePcioneS de PotencialeS BeneficiarioS 
de la inStitUcionalización de Un ProceSo de evalUación de 
tecnologíaS SanitariaS en cHile: Un eStUdio cUalitativo
Lavin C1, Alaniz R2, Espinoza MA3
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad de Chile, Santiago, Chile, 
3Catholic University of Chile, Santiago, Chile
ObjectivOs: La implementación de un proceso de evaluación de tecnologías sani-
tarias (ETESA) en Chile ha visto un lento desarrollo durante los últimos 20 años. 
Recientemente el Ministerio de Salud de Chile ha elaborado una propuesta de 
institucionalización que podría acelerar la discusión social. Sin embargo, no existe 
PHP40
clinical trial trendS in latin america: commUnicaBle verSUS  
non-commUnicaBle diSeaSe
Anderson R, Wilson T
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Following the recent economic growth in Latin America, this analysis 
was undertaken to analyse the corresponding shift in healthcare trends, by examining 
the number of clinical trials being conducted in the region and their changing focus 
on non-communicable and communicable diseases. MethOds: ClinicalTrials.gov 
was searched in March 2015 for all trials with a study start date from January 2000 to 
December 2014 in five Latin American countries: Brazil, Chile, Colombia, Mexico and 
Peru. Studies were classified as either communicable or non-communicable according 
to the World Health Organization International Classification of Disease-10 (WHO ICD-
10), with studies that did not focus on disease or illness excluded. Results: Between 
the five selected Latin American countries there were a total of 8,847 relevant studies 
identified, 46.3% of which originated from Brazil. Over the entire time period from 
2000 to 2014, 89.3% of studies were concerning non-communicable diseases such as 
cancer, cardiovascular disease and musculoskeletal disorders, whilst 10.7% focused 
on communicable diseases. An analysis over time saw a trend of an increasing propor-
tion of trials in non-communicable diseases and a fall in the proportion of studies in 
communicable diseases. In 2000, non-communicable diseases accounted for 77.8% of 
studies, compared with 22.2% in communicable diseases, however by 2014 these per-
centages were 93.4% and 6.6%, respectively. There were 711 unique studies across the 
countries in communicable disease; 24.9% of these were in HIV/AIDs, one of the most 
deadly, infectious diseases in the region, responsible for approximately 7.2 deaths per 
100,000 people across the five selected countries. cOnclusiOns: The healthcare 
trends of Latin America appear to be changing alongside its rapid economic expan-
sion; fewer clinical trials are being carried out in preventable, infectious diseases 
more commonly associated with poor healthcare availability and substandard living 
conditions, and there is an increasing focus on non-communicable diseases such as 
neoplasms, obesity and dementias.
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governance, deciSion-making, and UniverSal HealtH coverage: 
PercePtionS from cHilean HealtH deciSion-makerS
Saavedra MA1, Greer SL2, Méndez CA1
1Universidad Austral de Chile, Valdivia, Chile, 2University of Michigan, Ann Arbor, Ann Arbor, 
MI, USA
Objectives: To explore health decision-makers’ perceptions on governance on 
decision-making process within the región de Los Ríosintegrated healthcare deliv-
ery network. MethOds: A descriptive and exploratory qualitative study base on 
in-depth interviews with health decision-makers from región de Los Ríosfrom 
June 2013 to December 2014 was conducted. A convenience sample of 11 health 
decision-makers was selected. A health decision-maker was defined as a health 
professional with a formal policy or managerial status whose primary responsibility 
would be formal leadership on decision-making (i.e. Health Service Director, and 
Hospitals Directors). The interviews were performed, recorded -previous signing of 
the informed consent- and transcript literally. The interviews’ analysis was per-
formed through the content analysis technique in its conventional approach, using 
ATLAS.ti qualitative software. Results: For the health decision-makers, a meaning 
of governance applied to health systems and services is not conceived in a technical 
approach. Moreover, governance is neither perceived as a concept related to health 
nor universal health coverage. Politics was perceived as a key issue at designing 
and implementing health decision-making processes among the Chilean health 
systems. From a governance perspective, politics of health policy is perceived as a 
strong root for health decision-making in Chile. cOnclusiOns: the Chilean case 
highlights is the paradox that establishing good enough governance to implement 
central initiatives with effective integrity might involve accountability measures 
that interfere with good administration.
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Brazilian gUideline for academic detailing: a need to imProve 
HealtH care
Costa Jd1, Almeida-Brasil CC2, Lemos LL1, Gomes RM1, Acurcio FA1, Álvares J2,  
Guerra Júnior AA1
1CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal 
University of Minas Gerais, Belo Horizonte, Brazil
Objectives: To develop a Brazilian Guideline on Academic Detailing (AD) – 
educational outreach visits to prescribers. The overall aim is to enhance the 
rational use of medicines and devices provided by the Brazilian National Health 
System (SUS). MethOds: This document was based on an extensive search of 
the literature, the AD experience of international organizations and the expe-
rience of a pilot project conducted by the SUS Collaborating Centre in Belo 
Horizonte, Brazil. A team of 15 researches, including facilitators and coordina-
tors of AD Programs participated in the development of this Guideline. Results: 
The Guideline provides an overview of the AD service that should be per-
formed by a qualified and trained health professional (facilitator). To develop 
an AD Program a technical team composed of specialists on the subject to be 
addressed, researchers and interns should be formed. It is recommended that 
at least one coordinator manage the process, orient staff members, and conduct 
the training of facilitators. The process to develop and conduct an AD Program 
involves ten stages. Stage 1: Prospection and identification of problems; Stage 2: 
Definition of the AD purpose; Stage 3: Budget estimate, elaboration of schedule and 
technical team designation; Stage 4: Elaboration and purchase of the support mate-
rial; Stage 5: Identification of prescribers and organization of visitation goals; Stage 6: 
Recruitment of facilitators and workshop training; Stage 7: Prescribers’ visiting 
for AD; Stage 8: Release of the support material; Stage 9: Evaluation of results; 
Stage 10: Release of the results. cOnclusiOns: A national Guideline is neces-
sary to ensure the quality of AD service and the processes and outcomes that 
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inStrUmentoS Para la incorPoracion de la evalUacion economica, 
el imPacto PreSUPUeStario y loS eSqUemaS de Pago Por reSUltadoS en 
el Servicio catalán de SalUd (eSPaña)
Brosa M1, Puig-Junoy J2, Gasol-Boncompte M3, Segú-Tolsà L1, Gilabert-Perramon A4,  
Mora-Ripoll R5, Puig-Peiró R3
1Oblikue Consulting, Barcelona, Spain, 2Pompeu Fabra University, Barcelona, Spain, 3CatSalut, 
Barcelona, Spain, 4Government of Catalonia, Barcelona, Spain, 5CatSalut, Catalan Health Service, 
Barcelona, Spain
ObjectivOs: El Servicio Catalán de la Salud (Catsalut) como responsable de la 
gestión del sistema de salud en la Comunidad Autónoma de Cataluña, ha desarrol-
lado una sistemática dirigida a incorporar las innovaciones terapéuticas de forma 
coherente con su valor añadido. Con el objetivo de incorporar el valor social de la 
innovación y disminuir la incertidumbre sobre el mismo en el proceso de eval-
uación y adopción de nuevos medicamentos, el Catsalut ha desarrollado las Guías 
de Evaluación Económica y del Impacto Presupuestario (GAEIP) y la Guía para la 
definición de criterios de aplicación de Esquemas de Pago por Resultados (GEPR) en 
el ámbito farmacoterapéutico de Cataluña (España). MetOdOlOgíAs: Para elaborar 
las Guías se han seguido los siguientes pasos: (1) Revisión bibliográfica; (2) Análisis 
de experiencias internacionales y nacionales; (3) Elaboración del primer borrador; 
(4) Revisión y validación por expertos externos y (5) Revisión y elaboración de las 
Guías definitivas. ResultAdOs: La GAEIP es un instrumento compuesto de dos 
conjuntos de recomendaciones metodológicas y check-lists para guiar a las com-
pañías farmacéuticas en la realización de las evaluaciones económicas y de impacto 
presupuestario de los medicamentos que van a ser evaluados por el Catsalut. Por 
su parte, la Guía de EPR está compuesta de diferentes cuestionarios para ayudar a 
identificar aquellos medicamentos candidatos a un EPR (y de qué tipo) en función 
de las incertidumbres existentes y su grado, las preferencias y disponibilidad a 
pagar, y factores moduladores, organizativos e instrumentales. cOnclusiOnes: 
Los instrumentos desarrollados permitirán incorporar información sobre el valor 
económico de la innovación terapéutica disminuyendo la incertidumbre clínica y 
presupuestaria en el momento de su adopción por el sistema sanitario. Su imple-
mentación permitirá garantizar un acceso equitativo y una utilización sostenible 
de los nuevos medicamentos.
HealtH care USe & Policy StUdieS - Health Status/Population Health
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configUracion eSPacial de la vUlneraBilidad Social de inmigranteS 
internacionaleS en iqUiqUe 2002-2012 y SU relacion con la 
localizacion de red de atencion Primaria de SalUd
Vasquez A1, Cabieses B2
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad del Desarrollo, Santiago, 
Chile
ObjectivOs: (i) Caracterizar la configuración territorial de vulnerabilidad social de 
inmigrantes internacionales en la ciudad de Iquique, norte de Chile; (ii) Explorar la 
relación entre vulnerabilidad social y localización de atención primaria de salud 
(APS) para esta población. MetOdOlOgíAs: Estudio exploratorio de vulnerabilidad 
social de población inmigrante en Iquique a nivel de manzana censal utilizando 
Censo 2002 (n= 1266 manzanas) y 2012 (n= 1241 manzanas). La vulnerabilidad social 
fue medida a través de 3 de las dimensiones utilizadas en el Índice de Privación 
Múltiple (IMD: discapacidad, educación primaria y desempleo). El índice de cor-
relación de Pearson permitió comparar entre estas dimensiones. Además, se com-
pararon los límites territoriales de los 4 centros APS de Iquique con la distribución 
territorial de la vulnerabilidad social en inmigrantes en Iquique. ResultAdOs: 
Según censo 2002 y 2012 en Iquique habían 5.559 y 14.576 inmigrantes internac-
ionales respectivamente, concentrando el 4% de población inmigrante del país. La 
población inmigrante vulnerable se concentra en zonas de vulnerabilidad general: 
Cerro Dragón y distrito industrial de Iquique (correlación entre IMD población total 
y población inmigrante R= 0.41 en 2002 y R= 0.59 en 2012). La población más vulner-
able se encuentra en los límites territoriales de dos centros APS (Guzmán n= 36.708 
y Videla n= 40.601 inscritos), que concentran al 37% de los inmigrantes de todo 
Iquique. cOnclusiOnes: Existe heterogeneidad en la distribución espacial de la 
vulnerabilidad social en inmigrantes. Esta vulnerabilidad aumentó entre 2002 y 
2012 y se concentró en áreas de conocida vulnerabilidad para la población total. 
Inmigrantes vulnerables serían beneficiarios de centros APS con sobredemanda 
de servicios.
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a forma (in) adeqUada do aParato vocal
Chagas FA, Andrade VG
Instituto Federal de Goiás, Jataí, Goiás, Brazil
ObjetivOs: Esta pesquisa tem por objetivo discutir as implicações da voz de pro-
fessores pelo mau uso do aparelho fonador. MétOdOs: Estudo realizado com 22 
professores do ensino médio durante o ano de 2012, por meio de pesquisa quali-
tativa. ResultAdOs: 77,3% dos professores são do sexo feminino e 22,7% do sexo 
masculino, a média do tempo de profissão está entre 10 a 15 anos, a jornada semanal 
de trabalho de 41% deles é de trinta a quarenta horas semanais, sendo que 27,3% 
ministram até sessenta horas semanais. Quanto à intensidade da voz, 54,5% falam 
alto, sobre a velocidade da voz, 39% falam entre rápido e muito rápido. Quanto à 
alteração vocal todos já tiveram patologia laríngea, a maioria, 73% disseram apre-
sentar rouquidão e 27,0% já faltaram ao trabalho por perda de voz. Eles não tiveram 
nenhum tipo de orientação vocal sobre a maneira correta de usar a voz na comu-
nicação, 73% desconhecem a forma adequada de como usá-la e não se mantêm 
atualizados sobre o assunto. cOnclusões: Percebeu-se que mesmo com inúmeros 
recursos e avanços tecnológicos, os docentes abusam de sua voz, porque trabalham 
com sala de aulas lotadas, competem com inúmeros ruídos dentro e fora da sala, 
têm jornada muito extensa além de que faltam informações a eles sobre a forma 
información sobre las visiones y percepciones que otros actores (distintos al propio 
ministerio) tienen respecto de cómo debiera implementarse ETESA en Chile. El obje-
tivo de este estudio fue explorar/analizar las visiones/percepciones de potenciales 
usuarios y/o beneficiarios de un proceso de ETESA en Chile. MetOdOlOgíAs: 
Estudio cualitativo basado en el modelo de análisis de contenidos. Se llevaron 
a cabo 18 entrevistas semi-estructuradas a 19 personas. Se realizó un muestreo 
intencionado a un grupo de representantes que incluyó grupos técnicos (aca-
démicos y sociedades científicas), tomadores de decisión sobre adquisición de 
tecnologías del sector público y privado (pagadores y proveedores de salud), indus-
tria y sociedad civil (pacientes, asociaciones de consumidores). ResultAdOs: Las 
visiones fueron capturadas y organizadas en tres dimensiones: Principios que 
guías ETESA, Marco institucional e impactos esperados de su implementación. Los 
dos principios esenciales del proceso fueron transparencia y participación, para los 
cuales se obtuvieron variadas sugerencias para su implementación. Respecto de 
la institucionalidad, la mayoría opta por una entidad autónoma e independiente, 
liderada por un consejo directivo con amplia representación. Si bien se reconocen 
múltiples ventajas de contar con ETESA se identifican importantes desafíos para 
su implementación, entre ellos, la percepción de poco conocimiento del tema, 
escasa capacidades técnicas instaladas, y el que la implementación de ETESA 
no parece una prioridad actual en Chile. cOnclusiOnes: Existe consenso en 
torno a los principios que fundamentan la implementación de ETESA en Chile 
así como sus ventajas. Sin embargo, elementos como el limitado entendimiento 
de potenciales usuarios y la baja prioridad política amenazan su pronta 
implementación.
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a qUantitative analySiS of ten HealtH tecHnology aSSeSSment (Hta) 
agencieS for attriBUteS driving tranSParency of tHe organization
Mazumder D1, Kapoor A1, Gwatkin N2, Medeiros C3
1Optum Global Solutions, Noida, India, 2Geni Biopharma, Hampshire, UK, 3Optum Life Sciences, 
Minneapolis, MN, USA
Objectives: To quantitatively benchmark Health Technology Assessment (HTA) 
agencies for attributes of transparency. MethOds: We developed a Likert scale 
(0-5, higher score> best practice/ease of accession) to benchmark HTA agencies on 
standards for submission. This comprises 77 questions grouped into 18 principles 
(P1-P18) and 6 domains, namely, transparency, process, technical, equity, speed and 
implementation. Principles were weighted differentially to adjust for difference in 
number of questions under each principle. Here we present weighted analyses of 
the transparency domain for national agencies from 10 countries: Australia, Brazil, 
Canada, China, France, Germany, Japan, South Africa, Spain, and UK. Results: 
The principles under transparency (maximum possible score and weightage in 
parenthesis) were: P1- HTAs are unbiased, rigorous and transparent (10.5; 10.5%); 
P4 - HTAs incorporate appropriate methods depending on its goal (8.8; 9.4%); P12 
- HTAs are transparent in pricing, reimbursement and market access policies (4.1; 
3.5%); P14 - HTAs are transparent on recommendations around economic evalua-
tion (2.9; 7.0%).The overall weighted score for the transparency domain (maximum 
possible score: 26.3; higher scores indicating higher transparency) was highest 
for Australia (24.1), followed by France (23.9), UK (23.8), Germany (22.9), Canada 
(21.4), South Africa (20.1), Spain (17.9), Brazil (17.5), Japan (16.8) and China (9.6). 
Weighted score for P1 was highest for Australia and UK (9.5), followed by France 
(8.9) and Germany (8.5). For P4, the score was highest for Australia, Canada, France, 
Germany and UK (8.8, each). France scored highest for P12 (3.6) followed by Japan 
and Spain (3.4 each). Australia, Brazil, France, Spain, South Africa and UK scored 
highest for P14 (2.6 each). Our definition of HTA archetype placed Australia, France 
and UK at the highest level of HTA maturity (value implementers). cOnclusiOns: 
Transparency is a key attribute driving HTA maturity. More established the HTA 
agency, higher is the transparency in submission process, pricing policies, phar-
macoeconomic requirements and approach.
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defining market acceSS in Brazil: tHe PHarma ProfeSSionalS’ 
PerSPective
Nishikawa AM1, Santinho CS1, Julian G2, Piedade A1, Clemente V1
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil
Objectives: Innovation in healthcare has become increasingly expensive mak-
ing it difficult for pharmaceutical companies (PHARMAS) to have their products 
reimbursed. The Brazilian context is even more complex due to the current eco-
nomic crisis, complex incorporation pathway in the private market and accelerated 
growth of the generics market. Thus, most PHARMAS are strategically investing in 
the Public and Private Healthcare Market Access (MA) area. We aimed to analyze 
whether pharma professionals (PP) in Market Access understand the importance, 
challenges and requirements of this new area. MethOds: We conducted a survey 
with PP (sales, marketing, medical affairs, market access) from various PHARMAS 
in 2014, consisting of a questionnaire with open questions about the definition of 
market access and challenges or doubts about the topic. Results: A total of 136 
professionals from 6 different multinational PHARMAS answered the survey. We 
observed a great dissonance about their definition of market access. Most respond-
ers believed MA should focus on patients’ access, not just to drugs, but also to 
procedures and hospitalizations. About 75% (n = 102) stated concerns and obstacles 
to MA success. The majority focused on asking how to obtain specific product incor-
poration, and which were the pathways and criteria for technology incorporation in 
both public and private Brazilian healthcare systems. Most reported difficulties are 
the lack of integration between MA and other areas in the company, dissonance of 
objectives and points-of-view among healthcare players and the lack of qualified 
professionals in Brazil. cOnclusiOns: There was a great disparity in the defini-
tions of what is market access, most likely due to the relatively recent interest in 
the area in Brazil. Also, many PP still do not have enough training to build a suc-
cessful MA strategy, besides lacking the necessary integration with other areas to 
achieve their objectives.
